---

Related Articles:

Leukotriene modifiers in the treatment of asthma. Look promising across the board of asthma severity.

1998-04-25

[BMJ 316(7140) , 1257-8, (1998)]

BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice.

2007-09-01

[J. Physiol. Pharmacol. 58(3) , 583-8, (2007)]

Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse.

1999-09-09

[J. Vet. Pharmacol. Ther. 20(4) , 296-307, (1997)]

Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005.

1997-12-01

[J. Physiol. Pharmacol. 48(4) , 529-36, (1997)]

Ineffective elimination of Leishmania major by inflammatory (MRP14-positive) subtype of monocytic cells.

2000-11-01

[Immunobiology 202(5) , 442-59, (2000)]